

Å  
 Å  
 Å  
 24 September 2025  
 Å

**Medcaw Investments plc**  
 (â€œMedcawâ€ or the â€œCompanyâ€)  
 Å  
**Issue of Convertible Loan Notes**

Å  
 Å

Medcaw Investments plc (LSE: MCI ) announces that it has raised a total of Å£550,000 through the issue of unsecured convertible loan notes (â€œCLNsâ€ or â€œNotesâ€). The facility has a total nominal capacity of Å£600,000, with Å£425,000 subscribed in cash and a further Å£125,000 issued in lieu of fees.

Å  
 The proceeds of the CLNs will be applied towards supporting the Companyâ€™s working capital and capital expenditure requirements. The Notes carry an annual coupon of 6%, which is payable on redemption. In the event of non-payment on redemption, default interest will accrue at a rate of 12% per annum. The Notes are redeemable at par on the first anniversary of issue, or earlier in the event of a material breach, insolvency or other event of default.

Å  
 On completion of a â€œQualifying Transactionâ€ â€” being an IPO or admission of the Companyâ€™s shares to the London Stock Exchange, AIM or another recognised investment exchange requiring the publication of a prospectus â€” all outstanding Notes will automatically convert into fully paid ordinary shares of the Company at a conversion price of Å£0.01 per share.

Å  
 In addition, Noteholders will, upon conversion, be granted warrants to subscribe for one new ordinary share for every two shares received on conversion. The warrants will carry an exercise price of Å£0.03 per share and will be exercisable for a period of 12 months from the date of grant.

Å  
 No application has been, or will be, made for the Notes to be admitted to trading on any market.

Å  
 ENDS

Å  
 Medcaw Investments plc  
 Charlie Wood  
 Tel +44 (0)203 918 8797  
 For more information please visit: <https://medcaw-invest.com/>

Å Å  
 Broker / Corporate Adviser  
 GIS  
 James Sheehan  
 Tel: +44 (0)20 7048 9400

Å  
 Å  
**Market Abuse Regulation (MAR) Disclosure**

Å  
 The information set out below is provided in accordance with the requirements of Article 19(3) of the Market Abuse Regulations (EU) No. 596/2014 which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR').

Å

---